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Abstract
Background: In mucopolysaccharidosis type IIIB, a lysosomal storage disease causing early onset mental retardation in
children, the production of abnormal oligosaccharidic fragments of heparan sulfate is associated with severe
neuropathology and chronic brain inflammation. We addressed causative links between the biochemical, pathological
and inflammatory disorders in a mouse model of this disease.
Methodology/Principal Findings: In cell culture, heparan sulfate oligosaccharides activated microglial cells by signaling
through the Toll-like receptor 4 and the adaptor protein MyD88. CD11b positive microglial cells and three-fold increased
expression of mRNAs coding for the chemokine MIP1a were observed at 10 days in the brain cortex of MPSIIIB mice, but not
in MPSIIIB mice deleted for the expression of Toll-like receptor 4 or the adaptor protein MyD88, indicating early priming of
microglial cells by heparan sulfate oligosaccharides in the MPSIIIB mouse brain. Whereas the onset of brain inflammation
was delayed for several months in doubly mutant versus MPSIIIB mice, the onset of disease markers expression was
unchanged, indicating similar progression of the neurodegenerative process in the absence of microglial cell priming by
heparan sulfate oligosaccharides. In contrast to younger mice, inflammation in aged MPSIIIB mice was not affected by TLR4/
MyD88 deficiency.
Conclusions/Significance: These results indicate priming of microglia by HS oligosaccharides through the TLR4/MyD88
pathway. Although intrinsic to the disease, this phenomenon is not a major determinant of the neurodegenerative process.
Inflammation may still contribute to neurodegeneration in late stages of the disease, albeit independent of TLR4/MyD88.
The results support the view that neurodegeneration is primarily cell autonomous in this pediatric disease.
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Introduction
Divergent events such as deposition of Aß in Alzheimer disease
[1], a-synuclein or neuromelanin in Parkinson disease [2,3],
disease-associated PrP
sc protein in prion disease [4], mutants
SOD1 protein in amyotrophic lateral sclerosis [5], viral proteins in
human immunodeficiency infection [6] or mutant huntingtin in
Huntington disease [7] initiate involvement of the immune system,
which in turn interacts with the nervous system and set the pace of
progressive neurodegeneration. Neurodegenerative diseases are
characterized by both local activation of resident microglia and
astrocytes and infiltration of leucocytes from the periphery.
Immune reaction can be toxic for neurons through the local
production of the inflammatory cytokines TNFa, IL-1 and IL-6
[8,9]. Inflammatory chemokines, especially the macrophage
inflammatory protein 1a (MIP1a), are also produced, stimulating
microglial activation and attracting peripheral inflammatory cells
to the brain parenchyma. Suppressing inflammation is regarded as
a potential therapeutic approach against the development of
neurodegeneration in AD and PD, especially with regard to the
relative protection conferred by the long-term use of non-steroidal
anti-inflammatory drugs [10,11].
Whereas the association of chronic neurodegeneration and
inflammation is well established, the causative links between these
events is debated. Series of evidence from studies performed in
animal models of chronic neurodegeneration suggest that
microglial activation might be primed by the ongoing pathology
rather than the opposite. The deletions of cytokine genes have
shown inconsistent, minor or no effect on disease progression in
mouse models of neurodegenerative disorders [12,13]. It is
moreover unclear how and to which extent inflammation alone
could account for events almost invariably associated with
PLoS ONE | www.plosone.org 1 May 2008 | Volume 3 | Issue 5 | e2296neurodegeneration, such as mitochondrial dysfunction [14],
altered axonal transport [15], altered calcium storage and
endoplasmic reticulum functions [16], or dysfunction of intracel-
lular protein degradation and macroautophagy pathways [17,18].
Here, we addressed causative links between abnormal metab-
olite accumulation, brain inflammation and disease marker
expression in a mouse model of pediatric neurodegeneration
accompanying lysosomal storage diseases. Brain inflammation was
documented in several of these diseases [19–25]. In mucopoly-
saccharidosis type III (MPSIII), the unique event responsible for
both cell pathology and brain inflammation is the production and
accumulation of partially digested, possibly abnormally sulfated or
acetylated oligosaccharide fragments of heparan sulfate (HS), a
specific type of glycosaminoglycan (GAG). Interruption of HS
oligosaccharide degradation is the consequence of a defect in one
of the four exoglycanases required for the removal of the a-linked
N-acetylglucosamine at the non-reducing end of the saccharide
chain. The production of HS oligosaccharides is associated to the
secondary accumulation of GM2 and GM3 gangliosides [26,27],
to the formation of large cytoplasmic inclusions in various brain
cell types [28], to the accumulation of subunit C of the
mitochondrial ATP synthase [29], and to the dysregulation of
GAP43 mRNA expression in brain tissue [30]. Early onset
neurological manifestations in children lead to severe progressive
mental retardation and premature death. Our gene therapy
studies in the mouse [31] and the dog (M. Ellinwood, J.M. Heard,
unpublished) models of MPSIII subtype B (MPSIIIB), a deficiency
of a-N-acetylglucosaminidase (NaGlu), showed that delivery of the
missing enzyme to the brain prevented pathology and clinical
manifestations. Here, we provide evidence that microglial cell
activation is primed by HS oligosaccharides at very early stage of
the disease, although suppression of microglial cell priming by HS
oligosaccharides does not modify the course of the neurodegen-
erative process.
Results
HS oligosaccharides activate microglial cells
We examined whether microglial cell activation could be
induced by HS oligosaccharides. For that purpose, HS oligosac-
charides were purified from the urines of two MPSIIIB patients
(HS1 and HS2, see materials and methods and figure S1). Tandem
mass spectrometry analysis identified HS oligosaccharide species
previously detected in MPSIIIB patient urines [32] and in the
brain of MPSIIIB dogs (M. Fuller, M. Elinwood and J. Hopwood,
unpublished). It is therefore presumable that these molecules also
accumulate in the brain of MPSIIIB mice. Normal mouse
microglia cultures incubated with purified HS oligosaccharides
released TNFa in culture supernatant (table 1) and showed
morphological changes typical of cell activation (figure S2). This
phenotype was similar to that induced by LPS. Morphological
changes and release of TNFa in response to the stimulation by HS
oligosaccharides were however not suppressed by polymixin B, a
reagent that specifically inhibits LPS and other endotoxin action
(table 1). Microglial cell activation induced by HS1 or HS2 led to
increased detection of TNFa, IL1ß and MIP1a mRNAs (figure 1).
Compared to LPS, HS oligosaccharides induced lower expression
of TNFa mRNAs but equivalent levels of IL1ß and MIP1a
mRNAs. Synthetic heparin, purified bovine HS and GAGs
purified from normal individual urine did not activate microglial
cultures (table 1, fig. 1 and figure S2). Microglial cell activation was
much less intense when microglial cell cultures were derived from
mice deficient for the expression of the innate immune response
receptor Toll Like Receptor (TLR) 4 or the TLR adaptor protein
MyD88 (figure 1). These results indicate that HS oligosaccharides
produced by NaGlu deficient organisms stimulated microglial cell
activation through the TLR4/MyD88 signaling pathway. Inter-
estingly, higher amounts of IL1ß and MIP1a mRNAs were
produced by microglial cells isolated from MPSIIIB mice in
response to both LPS and HS oligosaccharides compared to wild
type mouse microglia, suggesting higher susceptibility to innate
immune stimulation (figure 1).
With the aim to examine relationships between microglial cell
priming by HS oligosaccharides and the progression of neuroin-
flammationandneurodegenerationinthebrainwithage,we studied
MPSIIIB mice and produced MPSIIIB mice deficient for the
expression of TLR4 or MyD88. As expected, MPSIIIB mice and
doubly mutant MPSIIIB6TLR4
2/2 or MPSIIIB6MyD88
2/2
mice accumulated equivalent amounts of HS oligosaccharides in
the brain, as appreciated by measuring GAGs in tissue extracts
(figure 2).
Priming of microglial cells is already prominent in the
brain of 10-days-old MPSIIIB mice
Brain cortical sections were immunostained for CD11b, a
marker of microglial cells (figure 3A). Expression of CD11b was
more intense in 10-days-old MPSIIIB mice than in age-matched
wild type mice. Positive cells showed ramified morphology. IL1ß
mRNAs were not expressed at significant level in 10-days-old
MPSIIIB mice (figure 3D). However, MIP1a mRNA levels were
already 3-folds higher than in wild type mice (figure 3C). Increased
CD11b staining and MIP1a mRNAs expression suggested early
priming of microglia in the brain of MPSIIIB. In doubly mutant
mice, CD11b expression was lower than in MPSIIIB mice and
equivalent to wild type mice. Increased MIP1a mRNA expression
was not observed in the brain. These results suggest that increased
CD11b and MIP1a mRNA expression in MPSIIIB mice
depended on TLR4 and MyD88. Since HS oligosaccharides are
already produced in NaGlu deficient mice at 10 days, this result is
Table 1. Activated microglial cells release TNFa in culture
supernatant.
Inducer Concentration
TNFa (pg/ml)u
Without PMB*
TNFa (pg/ml)u
with
PMB*(10 mg/ml)
None ,10 ND
Desulfated Heparin 5 mg/ml ,10 ND
Bovine HS 5 mg/ml ,10 ND
Normal GAG 5 mg/ml ,10 ND
LPS 0.5 mg/ml 125612
# ,10
LPS 1 mg/ml 581652 ,10
LPS 5 mg/ml 860639 ,10
HS2 0.5 mg/ml ,10 ,10
HS2 1 mg/ml 12611 2 61
HS2 5 mg/ml 26652 8 65
HS1 5 mg/ml 59674 5 66
uTNFa was detected in culture supernatants by ELISA (see materials and
methods)
*PMB: polymyxin B, a drug that competes with endotoxin binding to TLR4.
Absence of inhibition in the presence of PMB suggests that microglial
activation was not induced by endotoxins.
#Values are means6SEM from 3 experiments, in which 3 microglial cell cultures
were established from different mice.
doi:10.1371/journal.pone.0002296.t001
Neuroinflammation in MPSIIIB
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in 10-days-old MPSIIIB mice.
Mouse brain cortices were examined for altered expression of
disease markers (figure 3B and C–F), including GM2 and GM3
ganglioside accumulation, cell vacuolation (not shown), ScMAS
immunostaining and GAP43 mRNA expression level. MPSIIIB
mice showed reduced expression of GAP43 mRNAs and a mild
increased of ScMAS reactivity compared to age-matched wild type
mice. Similar reduction of GAP43 mRNA detection and augmen-
tation of ScMAS staining were observed in cortical extracts from
doublymutantmice,indicatingthatthesealterationscouldtakeplace
in the absence of microglial cell priming by HS oligosaccharides.
Inflammation was reduced but pathology was severe in
doubly mutant mice at 3 months
CD11b staining was dramatically increased in the brain of
MPSIIIB mice at 3 months, compared to age-matched wild type
mice (figure 4A). Staining was also more visible in doubly mutant
mice than in wild type mice, though much less intense than in
MPSIIIB mice. In all cases, CD11b positive cells conserved their
ramified morphology. IL1ß and MIP1a mRNAs were dramati-
cally increased in 3-months-old MPSIIIB mice (figure 4C, D). In
contrast, doubly mutant mice showed normal levels of IL1ß
mRNAs and normal or slightly increased levels of MIP1a mRNAs.
These results show that the development of inflammation in the
brain of 3-months-old MPSIIIB mice was primarily the conse-
quence of microglial cell priming involving TLR4 and MyD88.
To further document the role of HS oligosaccharide in this
response, we treated MPSIIIB mice by gene therapy at the age of 6
weeks. Delivery of the missing enzyme NaGlu in the brain of
MSIIIB mice normalized GAG levels in brain extracts (figure 2).
CD11b staining in cortical sections was much less intense than in
untreated mice, though slightly above levels detected in wild type
mice (figure 4A). Detected IL1ß mRNA amounts were also slightly
above wild type mouse level, though difference was not significant.
MIP1a mRNA levels were equivalent to wild type mice
(figure 4C,D). These results show that the alteration of
inflammation markers in MPSIIIB mice was secondary to GAG
accumulation, very low residual expression in treated mice being
consistent with very low residual production of HS oligosaccha-
rides, as expected since the therapeutic enzyme is not delivered to
all brain cells [31].
All disease markers were affected in MPSIIIB mice at 3 months
(figure 4B and E–H). GM2 and GM3 ganglioside levels were higher
than in age-matched wild type mice. Large cytoplasmic inclusions
were visible in various cell types including neurons, astrocytes,
microglia, endothelial, epithelial and meningeal cells (examples are
shown in figure S4). Immunostaining for ScMAS was increased.
GAP43 mRNA levelswere low compared to wild type, as previously
shown [30]. Enzyme delivery by gene therapy and prevention of
GAG accumulation was associated with a complete normalization
of disease markers (figure 4B and E–H), indicating that toxic effects
on brain cells were secondary to HS oligosaccharide accumulation.
Disease markers were similarly detected in MPSIIIB and doubly
mutant mice (figure 4B and E–H), indicating that neurodegener-
Figure 2. GAG accumulate in the brain of MPSIIIB mice. Wild
type mice (0, white bars), MPSIIIB mice (1, red bars), MPSIIIB6TLR4
2/2
mice (2, yellow bars), MPSIIIB6MyD88
2/2 mice (3, green bars), or
MPSIIIB mice in which the genetic defect was corrected in the brain by a
single intracerebral injection of AAV2.5-hNaGlu vector (4, blue bars)
were analyzed at the age of 10 days, 3 months, or 8 months. GAG
concentration was determined in cortical tissue extracts. Values are
means6SEM. Asterisks indicate significant difference with wild type
mouse values, crosses indicate significant difference with MPSIIIB values
(p,0.05, Mann and Whitney test).
doi:10.1371/journal.pone.0002296.g002
Figure 1. Heparan sulfate oligosaccharides activate mouse
microglial cells in vitro. Microglial cell cultures were established
from wild type (white bars), MPSIIIB (red bars), TLR4
2/2 (yellow bars), or
MyD88
2/2 (green bars) mice. Cells were incubated for 4 hours with
normal medium (mock), 5 mg/mL heparin (Hep), 5 mg/mL bovine
heparan sulfate (bHS), 5 mg/mL of GAG purified from normal individual
urine (nGAG), 1 mg/mL LPS (LPS), 5 mg/mL of heparan sulfate purified
from the urines of two MPSIIIB patients (HS1 and HS2) or 10 mg/ml of
polyinosine-polycytidylic acid (p[I:C]). Normal mouse microglial activa-
tion is shown by increased amounts of TNFa, IL-1b, MIP1a mRNA
production following incubation with LPS, HS1 or HS2. More robust
responses of cells isolated from MPSIIIB mice is consistent with previous
in vivo microglial priming, possibly by heparan sulfate. Lower
expression by microglia from TLR4
2/2 or MyD88
2/2 mice indicates
signaling through these molecules, whereas activation persisted upon
stimulation by p[I:C], which binds TLR3. Total RNA was extracted,
reverse transcribed and amounts of cDNAs coding for TNFa, IL-1ß,
MIP1a, or the reference protein ARPO [53] were measured by Q-PCR.
Indicated values are means6SEM of ratios of TNFa, IL-1ß, MIP1a mRNAs
to ARPO mRNAs measured in three independent experiments.
doi:10.1371/journal.pone.0002296.g001
Neuroinflammation in MPSIIIB
PLoS ONE | www.plosone.org 3 May 2008 | Volume 3 | Issue 5 | e2296ation was not delayed when inflammation markers were absent or
expressed at low level. Therefore, disease development at 3 months
was mostly independent of microglial cell priming through TLR4
and MyD88.
Inflammation and pathology were severe in MPSIIIB and
doubly mutant mice at 8 months
Eight-months-old MPSIIIB mice showed severe inflammation
in the brain (figure 5A,C,D). CD11b staining was intense and
associated to astrocytosis, as shown by increased reactivity for glial
fibrillary acidic protein (GFAP), a marker of astrocytes (astrocytosis
was not detected at 10 days and was very mild at 3 months, figure
S3). Amounts of IL1ß and MIP1a mRNAs were high. Although
slightly milder than in MPSIIIB mice, inflammation was also
intense in the cortex of doubly mutant mice (figure 5A,C,D),
suggesting it was mostly independent of TLR4 and MyD88 at this
stage, in contrast to the observations made at 3 months. However,
the disappearance (IL1ß and MIP1a, figure 5 C,D) or the
reduction (CD11b, figure 5A) of inflammatory markers in treated
MPSIIIB mice (figure 5A,C,D) indicated that the inflammatory
reaction was nevertheless triggered by HS oligosaccharides,
although presumably through different mechanisms in aged mice
than in younger animals.
Figure 3. Microglial cell activation and pathology markers in the brain at 10 days. Wild type mice (0, white bars), MPSIIIB mice (1, red bars),
MPSIIIB6TLR4
2/2 mice (2, yellow bars), MPSIIIB6MyD88
2/2 mice (3, green bars) were analyzed at the age of 10 days. Inflammation markers were
studied in cortical samples stained with anti-CD11b antibody (green in A) and by measuring the relative amounts of MIP1a (C) and IL1ß (D) mRNAs by
quantitative RT-PCR. Disease markers were studied in cortical samples stained with the anti-ScMAS antibody (green in B), and by measuring the
relative amounts of GAP43 mRNAs (E) and the accumulation of GM2/GM3 gangliosides (F). Immunofluorescence (A and B): nuclei are stained in blue
with Hoescht, scale bars: 20 mm for CD11b, 50 mm for ScMAS. Representative pictures from 3 MPSIIIB, 3 MPSIIIB6TLR4
2/2 and 3 MPSIIIB6MyD88
2/2
examined mice. RT-Q-PCR (C, D, E): mRNA amounts are expressed relative to the reference ARPO mRNA [53]. Asterisks indicate significant difference
with wild type mice and crosses indicate significant differences with untreated MPSIIIB mice (p,0.05, Mann and Whitney non-parametric test).
Number of mice used for GAG, gangliosides and mRNA analyses: wild type mice, n=6; MPSIIIB mice, n=6; MPSIIIB6TLR4
2/2 mice, n=5;
MPSIIIB6MyD88
2/2 mice, n=2.
doi:10.1371/journal.pone.0002296.g003
Neuroinflammation in MPSIIIB
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MPSIIIB mice at 8 months than at 3 months (figure 5B and E–H):
GM2 and GM3 ganglioside levels were higher, cell vacuolation
was more prominent and ScMAS immunostaining was more
intense. GAP43 mRNA levels, which decrease with age in wild
type mice, at the opposite increased in MPSIIIB mice, switching
Figure 4. Microglial cell activation and pathology markers in the brain at 3 months. Wild type mice (0, white bars), MPSIIIB mice (1, red
bars), MPSIIIB6TLR4
2/2 mice (2, yellow bars), MPSIIIB6MyD88
2/2 mice (3, green bars), or MPSIIIB mice in which the genetic defect was corrected in
the brain by a single intracerebral injection of AAV2.5-hNaGlu vector (4, blue bars) were analyzed at the age of 3 months. Inflammation markers were
studied in cortical samples stained with anti-CD11b antibody (green in A) and by measuring the relative amounts of MIP1a (C) and IL1ß (D) mRNAs by
quantitative RT-PCR. Disease markers were studied in cortical samples stained with the anti-ScMAS antibody (green in B), and by measuring the
relative amounts of GAP43 mRNAs (E), the accumulation of GM2/GM3 gangliosides (F), and the frequencies of vacuolated neurons or astrocytes (G)
and vacuolated microglia in cortical semi-thin sections (H). Immunofluorescence (A and B): nuclei are stained in blue with Hoescht, scale bars: 20 mm
for CD11b, 50 mm for ScMAS. Representative pictures from 3 MPSIIIB, 3 MPSIIIB6TLR4
2/2 and 3 MPSIIIB6MyD88
2/2 mice. RT-Q-PCR (C, D, E): mRNA
amounts are expressed relative to the reference ARPO mRNA [53]. Pathology (G and H): semi-thin sections (1 mm) were stained with toluidin blue. At
least 90 neurons/astrocytes were scored per mm
2 section surface. Values are from 3 MPSIIIB, 3 MPSIIIB6TLR4
2/2 and 3 MPSIIIB6MyD88
2/2 examined
mice. Examples of the morphology of cells that were scored as normal neurons or astrocytes, or vacuolated neurons or astrocytes are illustrated in
figure S4. Asterisks indicate significant difference with wild type mice and crosses indicate significant differences with untreated MPSIIIB mice
(p,0.05, Mann and Whitney non-parametric test). Number of mice used for GAG, gangliosides and mRNA analyses: wild type mice, n=7; MPSIIIB
mice, n=10; MPSIIIB6TLR4
2/2 mice, n=3; MPSIIIB6MyD88
2/2 mice, n=3; MPSIIIB+AAV2.5-hNaGlu mice, n=3.
doi:10.1371/journal.pone.0002296.g004
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PLoS ONE | www.plosone.org 5 May 2008 | Volume 3 | Issue 5 | e2296Figure 5. Microglial cell activation and pathology markers in the brain at 8 months. Wild type mice (0, white bars), MPSIIIB mice (1, red
bars), MPSIIIB6TLR4
2/2 mice (2, yellow bars), MPSIIIB6MyD88
2/2 mice (3, green bars), or MPSIIIB mice in which the genetic defect was corrected in
the brain by a single intracerebral injection of AAV2.5-hNaGlu vector (4, blue bars) were analyzed at the age of 8 months. Inflammation markers were
studied in cortical samples stained with anti-CD11b antibody (green in A) and by measuring the relative amounts of MIP1a (C) and IL1ß (D) mRNAs by
quantitative RT-PCR. Disease markers were studied in cortical samples stained with the anti-ScMAS antibody (green in B), and by measuring the
relative amounts of GAP43 mRNAs (E), the accumulation of GM2/GM3 gangliosides (F), and the frequencies of vacuolated neurons or astrocytes (G)
and vacuolated microglia (H). Immunofluorescence (A and B): nuclei are stained in blue with Hoescht, scale bars: 20 mm for CD11b, 50 mm for ScMAS.
Representative pictures from 3 MPSIIIB, 3 MPSIIIB6TLR4
2/2 and 3 MPSIIIB6MyD88
2/2 mice. RT-Q-PCR (C, D, E): mRNA amounts are expressed relative
to the reference ARPO mRNA [53]. Pathology (G and H): semi-thin sections (1 mm) were stained with toluidin blue. At least 90 neurons/astrocytes
were scored per mm
2 section surface. Values are from 3 MPSIIIB, 3 MPSIIIB6TLR4
2/2 and 3 MPSIIIB6MyD88
2/2 examined mice. Examples of the
morphology of cells that were scored as normal neurons or astrocytes, or vacuolated neurons or astrocytes are illustrated in figure S4. Asterisks
indicate significant difference with wild type mice and crosses indicate significant differences with untreated MPSIIIB mice (p,0.05, Mann and
Whitney non-parametric test). Number of mice used for GAG, gangliosides and mRNA analyses: wild type mice, n=5; MPSIIIB mice, n=10;
MPSIIIB6TLR4
2/2 mice, n=4; MPSIIIB6MyD88
2/2 mice, n=1; MPSIIIB+AAV2.5-hNaGlu mice, n=3.
doi:10.1371/journal.pone.0002296.g005
Neuroinflammation in MPSIIIB
PLoS ONE | www.plosone.org 6 May 2008 | Volume 3 | Issue 5 | e2296from abnormally low levels in young mice to abnormally high
levels in aged mice, as previously described [30]. Similar features
were observed in doubly mutant mice (figure 5B and E–H),
whereas 8-months-old mice that received gene therapy were
similar to age-matched wild type mice (figure 5B and E–H). This
observation confirmed that the toxic effects of HS oligosaccharides
on the brain of ageing mice were mostly independent of microglial
cell priming through TLR4 and MyD88.
Discussion
In MPSIII, neuroinflammation and neuropathology are caused
by the production and accumulation of HS oligosaccharides that
are absent in normal cells. The aim of the present study was to
examine causative links between HS oligosaccharide accumula-
tion, inflammation and disease markers in the cortex of MPSIIIB
mice. Our approach associated microglial cell cultures, modula-
tion of brain inflammation in cross-bred mice and disease
correction by gene therapy. Results provided evidence that HS
oligosaccharides primed microglial activation through TLR4 and
MyD88 both in vitro and in the MPSIIIB mouse brain. However,
suppression of microglial priming in MPSIIIB mice deleted for
TLR4 and MyD88 showed dissociation between inflammation,
which was absent or drastically reduced in young animals (10 days
and 3 months), and expression of disease markers, which was
unchanged. We conclude that neurodegeneration progresses
independently of the stimulation of the innate response by HS.
Nevertheless, injuries subsequent to the degenerative process
progressively created a chronic inflammatory state in the brain of
ageing MPSIIIB mice (8 months), which was independent of
TLR4 and MyD88, and which in turn may have exacerbated
pathology. Injuries that possibly stimulated chronic inflammation
in ageing MPSIIIB mice are the alteration of the blood-brain
barrier, as documented in mice with GM1 or GM2 gangliosidosis
[20], the secondary accumulation of GM2 and GM3 ganglisosides
[33] and the cell death.
Microglial activation by HS oligosaccharides is consistent with a
previous report showing that these molecules activate dendritic cells
through TLR4 [34]. Our experimental controls indicated that only
HS oligosaccharides, and not non-fragmented HS or chondroitin
sulfate activated microglia in vitro. HS oligosaccharide fragments
are produced in early endosomes by heparinases and thereafter
transferred to lysosomes for further digestion by exoglycanases. The
size of abnormal undigested oligosaccharides accumulating in
exoglycanase deficient cells, such as oligosaccharides with terminal
a-linked N-acetylglucosamine in MPSIIIB, ranges from single to
multiple repeats of disaccharides. Further studies will specify the
structure, sulfation and acetylation of HS oligosaccharide species
responsible for priming microglial activation.
In vitro assays showed a moderate effect of HS oligosaccharides
with respect to TNFa mRNA production and a much more robust
effect on MIP1a and IL1b mRNA expression. We therefore
focused in vivo studies on the latter two factors. They are
principally produced in the brain by activated microglia and/or
astrocytes. In 10-days-old MPSIIIB mice, we observed increased
CD11b staining and normal GFAP staining, suggesting that
MIP1a and IL1b mRNAs were produced by activated microglia.
Although GAG concentration in brain extracts was still in the
normal range at this stage, abnormal HS oligosaccharides were
already produced because of the enzyme defect, and therefore
possibly triggered microglial cell priming. Other stimuli that could
trigger microglial cell priming, like cell vacuolation and death
and/or secondary accumulation of GM2 and GM3 gangliosides
[35], were absent at this stage. Consistently with the stimulation of
microglial cell priming by HS oligosaccharides in the brain,
deletion of the innate immune response mediators TLR4 or
MyD88 in MPSIIIB mice showed substantial reduction of CD11b
staining and of the expression level of IL1b and MIP1a mRNAs at
10 days and 3 months, as observed in vitro.
Early MIP1a production in the MPSIIIB mouse brain is
reminiscent of the implication of this chemokine in the
neurodegenerative process associated with Sandhoff disease [36].
Possibly, oligosaccharides with terminal ß-linked N-acetylglucosa-
mine could prime microglia in this disease, as suggested [37].
Microglial activation and increased MIP1a gene expression were
also observed in the mouse models of GM1 and GM2
gangliosidoses before the onset of neurodegeneration [20].
An important observation in doubly mutant mice versus
MPSIIIB mice was the dissociation at 10 days, and more clearly
at 3 months, between the reduced expression of inflammation
markers and the severe expression of disease markers. Less intense
CD11b staining and reduced amounts of MIP1a and IL1ß
mRNAs were not associated with delayed occurrence of cell
vacuolation, ganglioside accumulation, detection of ScMAS or
altered expression of GAP43 mRNAs, which are relevant markers
of the progression of the neurodegenerative process in MPSs
[26,29,30,38]. Other markers were not investigated in doubly
mutant mice. They include brain cell apoptosis and Purkinje cell
loss, which were not consistently observed in MPSIIIB mice
[25,30,39]. The study of behavioral manifestations, which led to
controversial conclusions in MPSIIIB mice [28,31,39], and that of
the mean life-span were not performed because of the limited
number of available doubly mutant mice. Investigations of these
markers in Sandhoff mice showed delayed occurrence when
affected animals did not express MIP1a [36]. It remains to be
established whether the apparently different impact of priming of
the innate immune response in Sandhoff and MPSIIIB in mice is
due to difference in the courses of these diseases in mice, difference
in the mechanisms leading to brain inflammation, difference in the
invalidated innate immune response genes, or difference in the
investigated disease markers.
In MPSIIIB mice that received AAV vector mediated gene
therapy directed to the brain, microglial activation had been
primed by HS oligosaccharides before treatment. The clearance of
HS oligosaccharides after treatment was associated with the
absence of expression of disease markers and the very low, though
often still detectable expression of some inflammation markers,
including slightly increased CD11b signals and IL1ß mRNA
amounts. It is conceivable that trace amounts of residual HS
oligosaccharides production at locations in the brain where
enzyme delivery was less efficient led to persisting chronic
stimulation of the innate immune response. As a consequence,
these mice may be more susceptible to additional stimulation, as
proposed for prion disease in which priming of microglial
activation by Prp
sc exacerbated innate immune responses to
microbial pathogens [13]. This hypothesis is supported by the
observation that microglial cells isolated from MPSIIIB mice
produced higher amounts of MIP1a and IL1ß mRNAs in vitro in
response to LPS or HS oligosaccharides than wild type mouse
microglia. A further investigation of this issue in MPSIIIB mice is
worthwhile, since it may be relevant to the outcome of treatments
in children.
Our results indicate that inflammation may have different
causes and consequences depending on disease progression in the
brain of MPSIIIB mice. Priming of microglial activation by HS
oligosaccharides occurs at very early stage of the disease, whereas
pathology is still very mild. Activated microglia are thought to act
as effector cells in the degeneration of neural cells in the central
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capable of inducing intracellular swelled vesicles (beads) in neuron
dendrites and axons [40,41]. However, although this mechanism
might be relevant to the development of vacuolation and ScMAS
accumulation in MPSIIIB neuron, it is presumably not involved in
MPSIIIB since the appearance of these disease markers was not
delayed when microglial activation by HS oligosaccharides was
reduced in young doubly mutant mice. It is therefore likely that at
early stage of the disease pathology developing in the MPSIIIB
central nervous system is cell-autonomous rather than environ-
mental. Observation made in 8-months-old MPSIIIB and doubly
mutant mice suggest that the situation may be different at later
stage of the disease, when additional stimuli of innate immunity
subsequent to pathology development are likely predominant.
Responses to these stimuli is independent of TLR4 and MyD88
but may be exacerbated by the permanent stimulation of microglia
by HS oligosaccharides. They presumably induce a self-sustained
chronic inflammation that is potentially harmful to the central
nervous system.
Materials and Methods
Reagents
Media, fetal calf serum and antibiotics were from Invitrogen
(Carlsbad, California). Lipopolysaccharide (LPS, from Escherichia
coli 0111:B4), bovine HS (Heparin monosulfate sodium-potassium
salt), desulfated heparin (partially acetylated; semi-synthetic),
Polymyxin B, E-Toxate kit (Limulus Amebocyte Lysate, LAL) were
from Sigma (St Louis, MO, USA). Polyinosine-polycytidylic acid
(poly[I:C]) was from InvivoGen (Toulouse, France).
Patients, urine collection, HS oligosaccharide purification,
microglia cultures
- Patient 1 (11-years-old, GAG1 and HS1) and patient 2 (8-
years-old, GAG2 and HS2) were diagnosed for MPSIIIB before
the age of 5 years. Both had severe neurological manifestations at
the time of urine collection. Urines were collected under sterile
conditions and immediately stored at 220uC. According to the
French law (Code de la Sante ´ Publique, art. L1121-1), urine
collection without diagnostic or prospective investigation purpose
is not considered as Biomedical Research and therefore does not
require ethical committee approval.
- Isolation and characterization of HS oligosaccharides from
patient urine. GAGs were isolated as previously described [42].
Urines were acidified to pH 5.0–6.0 with acetic acid and
centrifuged. Cetylpyridinium chloride (CPC, 200 mL 5% w/v)
was added to supernatants for 12 hours at 4uC and centrifuged.
Pellets were successively washed with ethanol saturated with
sodium chloride, ethanol and ether, dried and resuspended in
0.6 mol/L NaCl at 4uC for 3 hours. After centrifugation,
supernatants with solubilized GAGs were precipitated with
ethanol at 4uC for 12 hours. Pellets were washed as before,
resuspended in water and used as GAG fraction.
- Isolation of HS from the GAG fraction was performed as
previously described [43]. GAG pellets were dissolved in 0.25 M
NaCl and applied on a Dowex 162 column (100–200 mesh, Cl
2
form) previously equilibrated with 0.25 M NaCl. After washing
with 0.25 M NaCl, stepwise elution of HS was performed with
0.5 M, 0.75 M, 1 M and 1.25 M NaCl. Fractions were assayed for
uronic acid content by hexuronic acid measurement [42] and
analyzed by cellulose acetate electrophoresis. Fractions containing
HS were pooled and precipitated with 4 volumes of ethanol at 4uC
for 12 h. After centrifugation, pellets were dried, resuspended in
water and used as HS fraction. Preparations used for microglia
activation assays were free of detectable endotoxin contaminant, as
shown by Limulus Amebocyte Lysate (LAL) assays. Oligosaccha-
rides in HS fractions were derivatised with 1-phenyl-3-methyl-5-
pyrazolone and analysed by ESI-MS/MS using a PE Sciex API
3000 triple quadrupole mass spectrometer as described previously
[32].
- Microglia cultures. Three day-old C57BL/6J mice were
obtained from Janvier Inc. (Le Genest-St-Isle, France). TLR4
deficient [44] and MyD88 deficient [45] C57BL/6J mice were
obtained from the laboratory of Shizuo Akira, backcrossed eight
times to the C57Bl/6 background and bred in the central animal
facility of the Pasteur Institute under SPF conditions. Primary
murine microglia cultures were prepared as previously described
[46]. Briefly, cerebral cortices without meninges were mechani-
cally and enzymatically dissociated with proteinase (10 U/mL)
and DNase (4000 U/mL). After adding of DMEM supplemented
with 10% endotoxin free heat-inactivated FBS and 50 mg/mL
gentamycin, cells were plated in DMEM 10% FCS on 100 mm
Petri dishes coated with 1.5 mg/mL poly-DL-ornithine (3 to
15 kDa) at a density of 3610
6 cells/dishes. Mixed glial cultures
were maintained at 37uC with 5% CO2 and medium was changed
after 4 days. After 12 days, dishes were shaken at 150 rpm for
90 min to detach non-adherent microglia. Detached cells were
collected and plated on either 24-well tissue culture plate slides or
in 6-well tissue plates at a density of 67,500 cells per cm
2 and
maintained at 37uC for 1 hour. After one hour at 37uC, loosely
adherent contaminating oligodendrocytes were removed from the
cultures. Adherent microglia was maintained at 37uC with 5%
CO2 for one day before treatment. Culture supernatants or total
RNAs were harvested at the indicated time after treatment and
stored at 280uC until assayed. Polymyxin B (10 mg/mL) was
added to cultures one hour before treatment with inducer.
- Immuofluorescence assays on microglia cultures. Antibodies:
mouse anti-rat ED1 monoclonal antibody (mAb, 1:200, clone
OBT1150, Immunological direct), rat anti-mouse CD11b mAb
(1:500, clone M1/70, BD Biosciences). Microglia seeded onto
15 mg/mL poly-DL-ornithine round coverslips was washed in PBS
and fixed with 4% paraformaldehyde for 15 minutes. After 3
washes with PBS, cells were incubated overnight at 4uC with
primary antibody in PBS, 1% bovine serum albumine (BSA), 2%
normal goat serum (anti-CD11b) or in PBS, 1% BSA, 2% normal
goat serum, 0.3% Triton (anti-ED1, anti-CD68, anti-GFAP).
Bound antibodies were revealed by one-hour incubation at room
temperature with Alexa Fluor 488 or 545-conjugated antibodies
(1:500, Invitrogen) and 1 mg/mL DAPI. Coverslips were mounted
in Fluoromount-G (Southern Biotech, Birmingham, AL). Obser-
vations were done on Axioplan 2 imaging optic microscope (Zeiss,
Le Pecq, France).
- Mouse TNF-a ELISA was from Biosource International
(Camarillo, CA, USA). Sensitivity was 10 pg/mL.
Mice, gene transfer to the brain, tissue processing and
analysis
- Mouse experiments were approved by the Institut Pasteur
ethical committee for animal research and performed by
authorized investigators (authorization no. 75–268, Ministe `re de
l’Agriculture et de la Pe ˆche). C57Bl/6
NaGlu+/2 MPSIIIB mice
were obtained from Pr. E. Neufeld (UCLA, Los Angeles, CA) [28].
C57Bl/6
TLR42/2 [44] and C57Bl/6
MyD882/2[45] mice were
obtained from the laboratory of Shizuo Akira. C57Bl/6
NaGlu2/2,
TLR42/2 and C57Bl/6
NaGlu2/2,MyD882/2 were generated by
breedingC57Bl/6
NaGlu+/2,TLR4+/2orC57Bl/6
NaGlu+/2,MyD88+/2,
respectively. Doubly mutant mice were identified by genotyping.
They were sterile and could not be propagated. Absence of NaGlu,
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Correction of the genetic defect and phenotype in the brain was
performed as described [31], using AAV vectors coding for the
missing enzyme NaGlu.
- Selection of single and doubly mutant mice. Genotype at
NaGlu, TLR4 and MyD88 loci was determined by PCR, using tail
DNA. Primers used for the detection of wild type alleles: a-N-
acetylglucosamine gene exon 6: forward: 59-TGGTCAGC-
CTGTGCTATGAG-39; reverse: 59-AGGTACCCAGCAAGAA-
GTGG-39. TLR4 gene exon 3: forward: 59-TGTTGCCCTTCA-
GTCACAGAGACTCTG-39; reverse: 59-CGTGTAAACCAGC-
CAGGTTTTGAAGGC-39. MyD88 gene exon 4: forward: 59-
AGCCTCTACACCCTTCTCTTCTCCACA-39; reverse: 59-
AGACAGGCTGAGTGCAAACTTGTGCTG-39. Primers used
for the detection of mutated alleles: a-N-acetylglucosamine gene
exon 6: forward: 59-GGAGAGGCTATTCGGCTATGACTG-39,
reverse: 59-GGACAGGTCGGTCTTGACAAAAAG-39; TLR4
gene exon 3: forward: 59-TGTTGCCCTTCAGTCACAGA-
GACTCTG-39, reverse: 59-ATCGCCTTCTATCGCCTTCTT-
GACGAG-39; MyD88 gene exon 4: Forward: 59-AGCCTCTA-
CACCCTTCTCTTCTCCACA-39, reverse: 59-ATCGCCTTCT-
ATCGCCTTCTTGACGAG-39
- Breeding procedures. MPSIIIB (NaGlu
2/2) were produced by
crossing NaGlu
+/2 mice and selection of the progeny on genotype.
Breeding of NaGlu
2/26NaGlu
2/2 was possible, though poorly
efficient. NaGlu
2/26TLR4
2/2 and NaGlu
2/26MyD88
2/2
were produced by selection of the progeny of cross-breeding
between NaGlu
2/2 and TLR4
2/2 or NaGlu
2/2 and Myd88
2/2.
Doubly mutant mice were sterile. All experiments involving
doubly mutant mice were therefore performed on F1 mice. The
absence of NaGlu activity was verified by enzyme assay in brain
extracts. The absence of detection of TLR4 or MyD88 was
verified by quantitative RT-PCR in brain extracts and by western
blot in liver extracts (table S1).- Adeno-associated virus vector and
vector production. The AAV2.5-hNaGlu vector is a hybrid AAV
vector in which the capsid is from the AAV5 serotype and the
genome from the AAV2 serotype. The vector genome contains the
Inverted Terminal Repeats (ITRs) of AAV2, the mouse phospho-
glycerate kinase-1 gene promotor (mPGK), the human NaGlu
cDNA [47] and the BGH polyadenylation sequence. A control
AAV vector was similarly constructed except that mPGK
promoter sequences were deleted. Vector batches were produced
by transient transfection of HEK293 cells and purified using two
successive CsCl gradients. Purified fractions were pooled and
dialysed against PBS/Ca
2+/Mg
2+ (Biowhitaker), as described [48].
Vector genomes (vg) were quantified by dot blot.
- Intracranial injections. Six-week-old MPSIIIB
2/2 mice were
anesthetized with ketamine/xylazine (0.1/0.01 mg/g body weight)
and installed on a stereotactic frame (David Kopf Instruments,
Tujunga, CA) (n=9). The skull was exposed by a small incision.
Five microliters of the AAV2.5-hNaGlu vector or the control AAV
vector (3610
9 vg) were injected into the striatum with a Hamilton
syringe with a 30-gauge blunt tip needle mounted to the stereotactic
frame (coordonates +0.7 mm anterior to bregma, 2 mm left lateral
to the midline and 4.5 mm depth). 2.5 ml of vector was delivered
with an ultramicropump (World Precision Instruments, Hertford-
shire, UK) at a rate of 500 nl/min. The needle was then brought up
0.5 mm and the rest of the volume was injected at the same rate.
The needle was slowly withdrawn, the scalp was closed and the
animals were returned to recovery cages.
- Brain tissue processing. Mice that did not receive AAV vector injection:
biochemistry, RT-PCR and imaging studies were all performed in
the same mouse. After perfusion with PBS, brains were removed
and hemispheres were separated. The right hemisphere was
collected for GAG assay. The left hemisphere was sliced. Cortical
fragments (3 mm
3) were collected for RT-PCR analysis, immu-
nofluorescence analysis and semi-thin sections. Fragments for RT-
PCR were immediately frozen in nitrogen and stored at 2135uC
until RNA extraction. Fragments for immunofluorescence were
fixed with 4% paraformaldehyde (PFA) for 1 hour at +4uC, rinsed,
immersed in 30% sucrose and embedded in O.C.T. (Tissue-tek,
Sakura) and stored at 280uC until cryosection. Fragments for
semi-thin sections were fixed by immersion with 3.6% glutaral-
dehyde at +4uC, post-fixed in 2% aqueous osmium tetroxide and
embedded in epon-araldite. Mice that received AAV vector injection:
treated MPSIIIB mice received the AAV2.5-hNaGlu vector.
These mice were used for either biochemical or pathology
analyses. Control normal mice received the control AAV vector.
These mice were used for biochemical analyses, providing
information about inflammatory response to AAV vector particle
injection in the brain. Biochemical analyses were performed using
cortical fragments collected from the injected hemisphere and
immediately frozen in nitrogen for RT-QT-PCR analysis. They
included enzyme activities and GAG assay. Pathology analyses
were performed after intracardial perfusion with 4% PFA. Brains
were removed, hemispheres were separated and cortical fragments
were collected. They were used for immunofluorescence and semi-
thin sections, as described below.
- Semi-thin sections. One-micrometer-thick sections were
prepared, stained with toluidine blue for 2 hours and examined
with a bright field microscope (Axiovision software, Carl Zeiss,
MicroImaging, Inc.). Images were acquired with a 1006objective
lens from 5 randomly chosen areas of the cerebral cortex.
- Immunofluorescence on brain sections. Ten mm coronal
cortex cryosections were incubated overnight at +4uC with biotin-
conjugated rat anti-mouse CD11b monoclonal antibody (1:200;
clone no. M1/70, BD Biosciences), rabbit anti-cow GFAP (1:500,
Dako) or anti-subunit c of mitochondrial ATP synthase (ScMAS)
rabbit serum (1:1000, a gift Pr. D. Palmer, Lincoln University,
Canterbury, New-Zeland). After pre-incubation in blocking buffer
(10% normal goat serum, 10% normal donkey serum in PBS for
anti-CD11b and anti-GFAP; 2% normal goat serum, 5% bovine
serum albumin, 0.02% saponin for anti-ScMAS) for 30 min at
room temperature, bound antibodies were revealed with strepta-
vidin Alexa FluorH 488 (1:1000, Molecular Probes, anti CD11b),
or goat anti-rabbit Alexa FluorH 647 (1:500, Invitrogen, anti-
GFAP and anti-ScMAS) for 1 hour at room temperature. Nuclei
were stained with Hoechst (1:500, Sigma), sections were mounted
with Fluoromount (Southern Biotech) and examined by confocal
fluorescence microscopy (CD11b, 636, LSM510, Carl Zeiss,
MicroImaging, Inc.) or fluorescence microscopy (GFAP, 206,
Axiovision software, Carl Zeiss, MicroImaging, Inc.). Images were
acquired from 3 to 6 randomly chosen fields.
- Lysosomal enzyme assays on brain sections. Anesthetized
animals were perfused with PBS and cerebral hemispheres were
separated. Tissue was homogenised in water, submitted to 10
freeze/thaw cycles and clarified by centrifugation at 13,000 rpm
for 3 min. NaGlu and total ß-hexosaminidases activities were
determined by fluorometric assays using 4 mM 4-methylumbelli-
feryl-N-acetyl-a-D-glucosaminide (Calbiochem) for 2 hours [49]
or 1 mM 4-methylumbelliferyl-2acetamido2deoxy-a-D-glucopyr-
anoside (Sigma) substrate for 5 minutes [50], respectively. One
catalytic unit corresponds to the hydrolysis of 1 nmol of substrate
per hour and expressed per mg of proteins in extracts. Protein
concentration was determined with a BCA protein assay kit with
bovine serum albumin as the standard.
- Analysis of glycosaminoglycans in brain extracts. Frozen
samples were homogenized with a minimum volume of water
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residues were digested overnight at 65uC with papain (0.3% w:v)
in 3 ml of 100 mM sodium acetate buffer pH 5.5 containing
5 mM cysteine and 5 mM EDTA. After centrifugation, GAGs
were measured in the supernatant with a dimethylmethylene blue
dye binding assay. Briefly, 200 ml of the supernatant was added to
2.5 ml of dimethylmethylene blue reagent [51] and the absor-
bance at 535 nm was measured. Heparan sulfate was used as
standard. Data (means of duplicates) were expressed as mgo f
GAGs per mg of dried pellet.
- Ganglioside assay. The analysis of gangliosides was performed
as has been previously described [52]. Data (mean of duplicates)
were expressed as mole percentage of total gangliosides.
Quantitative RT-PCR
- Procedure. Total RNA was extracted using Trizol (Invitrogen)
from approximately 300,000 cells or from 50 mg of cortex and
suspended in 30 mL of water. One microgram of total RNA was
used to synthesize cDNA with oligo (dT)12–18 (200 ng, Roche
Applies Science, Meylan, France) and M-MLV reverse transcrip-
tase (Superscript III, Invitrogen). Quantitative PCR was per-
formed in a Model 7000 Sequence Detector (Applied Biosystems,
Foster City, CA) with 100 ng of cDNA and the SYBR Green PCR
Master Mix (according to Applied Biosystems procedures).
Amplification parameters: 50uC for 2 minutes, 95uC for 10
minutes, 95uC for 15 seconds, 60uC for 1 minute. Each sample
was analyzed in triplicate. Negative controls included omission of
reverse transcriptase at the cDNA synthesis step and omission of
the template at the PCR step. Additional controls performed for
each cDNA amplification included optimization of primer
concentration, assessment of amplification efficiency and detection
of possible primer dimerization through analysis of dissociation
curves. Ct (Cycle threshold) values were determined as the
numbers of PCR cycles at which specific amplification of the target
sequence occurred. Ct superior to 38 were considered as
background signal. cDNA amounts were expressed as 2exp(Ct1–
Ct2), in which Ct1 is a reference Ct measured for the amplification
of ARPO (Acidic ribosomal phosphoprotein) cDNAs [53] and Ct2
is the Ct measured for the amplification of the examined cDNA.
Samples were analyzed in triplicate.
- Primers: ARPO, forward: 59-TCCAGAGGCACCATTGA-
AATT-39,r e v e r s e :5 9-TCGCTGGCTCCCACCTT-39;T N F - a,
forward: 59-GAGTGACAAGCCTGTAGCCCA-39,r e v e r s e :5 9-
GCGCTGGCTCAGCCAC-39; IL-1ß, forward: 59-CAACCAA-
CAAGTGATATTCTCCATG-39 reverse: 59-GATCCACACTC-
TCCAGCTGCA-39;M I P 1 a,f o r w a r d :5 9-CTGCAACCAAGT-
CTTCTCA-39,r e v e r s e :5 9-GCATTCAGTTCCAGGTCAGT-39;
GAP43, forward: 59-CACCATGCTGTGCTGTATGAGA-39,r e -
verse: 59-TGTTCAATCTTTTGGTCCCTCATCA-39.
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